Stock Price, Quote, News and Profile of PSYENCE BIOMEDICAL LTD(NASDAQ:PBM) stock

PSYENCE BIOMEDICAL LTD

NASDAQ:PBM (1/13/2025, 2:14:01 PM)

1.9

+0.2 (+11.76%)

Chartmill TA Rating

Chartmill Setup Rating

Sector

GICS SectorHealth Care

GICS IndustryBiotechnology

GICS SubIndustryBiotechnology

Chartmill FA Rating

Valuation

Growth

Profitability

Health

Dividend

Chartmill High Growth Momentum

EPS Q2Q%N/A

Sales Q2Q%N/A

CRS0

6 Month-92.7%

Overview

Earnings (Last)08-12 2024-08-12

Earnings (Next)N/A N/A

Ins OwnersN/A

Inst Owners13.21%

Market Cap1.61M

Shares850.00K

PEN/A

Fwd PEN/A

Dividend YieldN/A

AnalystsN/A

Short Float %N/A

Short Ratio0.02

IPO12-10 2021-12-10

Stock Screener Links

GICS Sector Stock Screener

Find competitors from the same sector on the USA

GICS Industry Stock Screener

Find competitors from the same industry on the USA

Technical Stock Screener

Find stocks with similar TA and Setup ratings on the USA

Fundamental Stock Screener

Find stocks with similar Fundamental rating on the USA

Best Technical Competitors Stock Screener

Find the competitors with the best technical ratings on the USA

Best Technical Setups Competitors Stock Screener

Find the competitors with the best technical and setup ratings on the USA

Best Fundamental Competitors Stock Screener

Find the competitors with the best fundamentals on the USA

Best Valuation Competitors Stock Screener

Find the competitors with the best valuation on the USA

Best Dividend Competitors Stock Screener

Find the competitors with the best dividend on the USA

Best Analyst Rating Competitors Stock Screener

Find the competitors with the best analyst ratings on the USA

Company Profile

Psyence Biomedical Ltd. is a life science biotechnology company. The company is headquartered in Toronto, Ontario. The company went IPO on 2021-12-10. The firm has partnered with iNGENu Pty Ltd (iNGENu) to conduct the Company’s clinical trial in palliative care. iNGENu is an Australia-based, globally focused contract research organization (CRO) with experience working in the psychedelic pharmaceutical drug development and clinical research industry. Its Phase IIb clinical trial, using PEX010, a 25mg naturally derived psilocybin drug candidate product in-licensed by the Company, in the palliative care setting.

Company Info

PSYENCE BIOMEDICAL LTD

121 Richmond Street West Penthouse, Suite 1300

TORONTO ONTARIO V6E 3Z3

P: 17744604171

CEO: John Plourde

Employees: 0

Website: http://psyence.com

PBM News

17 days ago - Psyence Biomedical Ltd.Psyence Biomed Announces Closing of $2.0 Million Private Placement

NEW YORK, Dec. 27, 2024 (GLOBE NEWSWIRE) -- Psyence Biomedical Ltd. (Nasdaq: PBM) (“Psyence Biomed” or the “Company”) today announced that it has closed...

21 days ago - Psyence Biomedical Ltd.Psyence Biomed Announces $2.0 Million Private Placement

NEW YORK, Dec. 23, 2024 (GLOBE NEWSWIRE) -- Psyence Biomedical Ltd. (Nasdaq: PBM) (“Psyence Biomed” or the “Company“) today announced that it has entered...

21 days ago - Psyence Biomedical Ltd.Psyence Biomedical Regains Full Compliance with All Nasdaq Continued Listing Requirements

Company poised to enter 2025 with cash position of $5.6 million and debt-free balance sheet...

a month ago - Psyence Biomedical Ltd.Psyence Biomed Highlights Recent Progress on Active Phase IIb Clinical Trial

Patient screening underway; first patient expected to be randomized into the study in January A leading clinical trial site management organization (SMO),...

a month ago - Psyence Biomedical Ltd.Psyence Biomed Executes Binding Agreements with Optimi Health Corp.

Psyence Biomed obtains exclusive worldwide supply rights to Optimi’s GMP-certified, nature-derived psilocybin for its drug development and...

a month ago - Psyence Group Inc.Psyence Group Enters into Agreements with its NASDAQ-Listed Associate, Psyence Biomedical, to settle outstanding obligations

TORONTO, Dec. 06, 2024 (GLOBE NEWSWIRE) -- Psyence Group Inc (

PSYENCE BIOMEDICAL LTD (PBM)

Nasdaq Stock Screener

USA Stock Screener